Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.63 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.63 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.63 |
| ▸ | DPP9 | Q86TI2 | 10/20 | 0.63 |
| ▸ | FAP | Q12884 | 9/20 | 0.63 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12733269 | 0.95 | DPP4 (0.57) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL17814291 | 0.87 | DPP4 (0.65) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL17814215 | 0.83 | DPP4 (0.66) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL6240873 | 0.79 | DPP4 (0.61) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL8602481 | 0.79 | DPP4 (0.61) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL8602483 | 0.79 | DPP4 (0.61) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL12343823 | 0.79 | DPP4 (0.61) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL14389854 | 0.78 | DPP4 (0.62) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL12285805 | 0.78 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL12285817 | 0.78 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333461-A1 | PEPTIDOMIMETIC INHIBITORS OF POST-PROLINE CLEAVING ENZYMES | BACH BIOSCIENCES, LLC | 2017-11-23 | — | — | US | disclosed |
| US-9757400-B2 | Peptidomimetic inhibitors of post-proline cleaving enzymes | TRUSTEES OF TUFTS COLLEGE (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160158260-A1 | Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes | BACH BIOSCIENCES, LLC | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333461-A1 | PEPTIDOMIMETIC INHIBITORS OF POST-PROLINE CLEAVING ENZYMES | PREP, PEPD, DNPEP | DPP4 5/4885DPP7 6/4885DPP8 11/4885 |
| US-20160158260-A1 | Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes | PREP, PEPD, DNPEP | DPP4 5/4885DPP7 6/4885DPP8 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.